Overview

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2018-04-30

Target enrollment:

Participant gender:

Summary

To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

Acetylon Pharmaceuticals Incorporated
Celgene

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Ricolinostat
Thalidomide